ClinicalTrials.gg
RecruitingNCT07363577NOVA2Updated Jul 27, 2026

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

A Phase 3 interventional study of LB-102 (50 mg tablet) and LB-102 (100 mg tablet) in Schizophrenia, sponsored by LB Pharmaceuticals Inc.. Recruiting at 13 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by LB Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Planned enrollment
109th of 1,319
456 · median 66
Started
2026
with 49 others
Phase 3
196 of 1,465
19 open now
Primary completion
2027-06
later than 62 of 165 live
Registered
1,422nd of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 109th largest by planned enrollment of the 1,319 interventional ones that give a count, is one of 50 that started in 2026, is one of 196 in phase 3, reaches primary completion later than 62 of the 165 other live ones, and was the 1,422nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

Read the detailed description

This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, multicenter study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of LB-102 100 mg once daily (QD) and LB-102 50 mg QD versus placebo QD for the treatment of adult patients with an acute exacerbation of schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • acute schizophrenia,
  • exacerbated acute schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide ICF
  • Willing to be hospitalized for duration of the study
  • Diagnosis of schizophrenia as defined by
  • - 18-40
  • PANSS 80-120

Exclusion criteria

Exclusion Criteria:

  • Sexually active m/f not willing to adhere to highly effect
  • Breast feeding
  • Increase in PANSS of > 20% between screening and baseline
  • History of resistant treatment to schizophrenia medications
  • diagnosis other than schizophrenia
  • Risk of suicidal behavior
  • Risk of violent or destructive behavior
  • tardive dyskinesia determined by a score of ≥3 on Item 8 of the AIMS at Screening
  • Score of ≥3 on the BARS global clinical assessment of akathisia at Screening
  • Insulin dependent diabetes
  • Known ischemic heart disease or any history of myocardial infarction, congestive heart failure (whether controlled or uncontrolled), angioplasty, stenting, or coronary artery bypass surgery
  • History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the patient
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
456 participants (estimated)

Study arms

  • Experimental
    LB-102 (50 mg tablet)

    • LB-102 50 mg given orally for 6 weeks

    Drug: LB-102 (50 mg tablet)

  • Experimental
    LB-102 (100 mg tablet)

    LB-102 100 mg given orally for 6 weeks

    Drug: LB-102 (100 mg tablet)

  • Placebo comparator
    Placebo

    Placebo given orally for 6 weeks

    Other: Placebo

Interventions

  • LB-102 oral tablet given for six weeks

    Also known as: LB-102

  • LB-102 oral tablet given for six weeks

    Also known as: LB-102

  • OtherPlacebo

    Placebo tablet given orally for six weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline to Week 6 on the Positive and Negative Syndrome Scale

    Determine whether LB-102, demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo: increase in scale indicates worsening while a decrease in the scale likely indicates a response to treatment

    Time frame: 6 weeks

Secondary outcomes

  1. Evaluate the Safety and Tolerability of LB-102

    Evaluate the safety and tolerability of LB-102 in patients by evaluating adverse events

    Time frame: 10 weeks

  2. Change in Clinical Global Impressions-Severity of Illness scale (CGI-S)

    Assess the effect of LB-102 on the treatment for schizophrenia, as determined by a change from Baseline in the Clinical Global Impressions Severity of Illness scale: whereas increase demonstrates worsening of illness and decrease in score likely indicates response to treatment

    Time frame: 6 weeks

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 15 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Jan 23, 2026
StartActual
Mar 25, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Oct 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07363577
Lead sponsor
LB Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Mar 25, 2026
Primary completion
Jun 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Branislav Mancevski, MD
Contact
clinicaltrials@lbpharma.us
212-605-0300

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LB-102

Start the discussion